Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
Completed · Phase 2, Phase 3 · NCT03346434
Conditions: Dermatitis, Atopic
At a glance
- Research payments reported, 2025
- $9,554
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 202
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Dupilumab (drug), Matching placebo (drug)
- Dates
- Started 2017-11-30; completion 2021-07-08
- Results posted
- Yes
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
From ClinicalTrials.gov, last updated 2022-07-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $9,554 in research payments for this study in 2025 (11 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $9,554
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.